Science 37, a Playa Vista, Calif.-based company focused on site-less clinical trials, raised $29m in Series C funding.
The round was led by Glynn Capital Management with participation from GV, Amgen Ventures, as well as participation from all existing investors Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint investment company), and Sanofi Ventures.
The company, which has raised nearly $67m in total invested capital since inception, intends to use the funds to speed additional development of the proprietary Science 37 NORAĀ® software platform, to scale the clinical operations teams and expand into new innovative markets and therapeutic areas, and to prepare for international expansion in the coming years.
Led by Noah Craft, MD, PhD, and co-founder and CEO, and Belinda Tan, MD, PhD, and co-founder and chief medical officer, Science 37 provides a proprietary tech platform to enable patients to access clinical trials from home via mobile devices and telemedicine services, and features virtual trial specialists, mobile nursing companies, and study monitors to execute clinical trial services for sponsors.
FinSMEs
25/04/2017